CD8A and myeloid sarcoma: RA-MTX patients displayed a vast increase in the percentage of responding CD8+ Tnaïve-like cells after the second vaccination, whereas MS-OCR patients displayed an increase in the percentage of responding CD8+ Tnaïve-like cells after the first vaccination which remained higher after the second vaccination (Figure 5e).